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endogenous nAChRα7 activation on the regulation of full-blown muscular inﬂammation in
mdx mouse with Duchenne muscular dystrophy. We used mdx mice with 3 weeks-old at
the height myonecrosis, and C57 nAChRα7þ/þ wild-type and nAChRα7/ knockout mice
with muscular injury induced with 60 mL 0.5% bupivacaine (bp) in the gastrocnemius
muscle. Pharmacological treatment included selective nAChRα7 agonist PNU282987
(0.3 mg/kg and 1.0 mg/kg) and the antagonist methyllycaconitine (MLA at 1.0 mg/kg)
injected intraperitoneally for 7 days. Selective nAChRα7 activation of mdx mice with
PNU282987 reduced circulating levels of lactate dehydrogenase (LDH, a marker of cell death
by necrosis) and the area of perivascular inﬂammatory inﬁltrate, and production of
inﬂammatory mediators TNFα and metalloprotease MMP-9 activity. Conversely,
PNU282987 treatment increased MMP-2 activity, an indication of muscular tissue remodel-
ing associated with regeneration, in both mdx mice and WTα7 mice with bp-induced
muscular lesion. Treatment with PNU282987 had no effect on α7KO, and MLA abolished the
nAChRα7 agonist-induced anti-inﬂammatory effect in both mdx and WT. In conclusion,
nAChRα7 activation inhibits muscular inﬂammation and activates tissue remodeling by4
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b r a i n r e s e a r c h 1 5 7 3 ( 2 0 1 4 ) 2 7 – 3 628increasing muscular regeneration. These effects were not accompanied with ﬁbrosis and/
or deposition of non-functional collagen. The nAChRα7 activation may be considered as a
potential target for pharmacological strategies to reduce inﬂammation and activate
mechanisms of muscular regeneration.
& 2014 Elsevier B.V. All rights reserved.1. Introduction
The nervous and immune systems are not fully independent.
In order to maintain homeostasis, both produce cytokines,
neurotransmitters and/or express receptors that act upon impor-
tant physiological functions (Gallowitsch-Puerta and Pavlov,
2007; Junger, 2011; Pena et al., 2011; Rosas-Ballina et al., 2011;
Tracey, 2002; Ulloa, 2013; Wang et al., 2004). The vagus nerve
system (VNS) exerts an essential role in the regulation of
inﬂammation via releasing endogenous acetylcholine (ACh) in
the parenchyma of innervated organs. Although predominantly
expressed in neuronal tissues, several types of immune cells,
including macrophages, also express nAChRα7 mRNA (AlSharari
et al., 2013), and reduction of inﬂammatory cytokine production
often occurs following nAChRα7 macrophage signaling (Bernik
et al., 2002). Moreover, in vitro treatment of lipopolysaccharide-
stimulated humanmacrophages with ACh reduces production of
pro-inﬂammatory cytokines (TNFα, IL-1β, IL-6, IL-18) but not of
the anti-inﬂammatory cytokine IL-10, and direct in vivo VNS
stimulation also prevented development of shock (Borovikova
et al., 2000). Likewise, ACh released from activate spleen T
lymphocytes interact with nAChRα7 on macrophages present
in the red pulp and marginal zone inhibiting TNFα production
(Andersson and Tracey, 2012; Rosas-Ballina et al., 2011) and B cell
antibody secretion (Andersson and Tracey, 2012), but activating
the release of the anti-inﬂammatory IL-10 cytokine from Th2
cells (Trakhtenberg and Goldberg, 2011).
The potential role of the cholinergic anti-inﬂammatory
pathway via VNS and nAChRs activation has been demon-
strated in various experimental models of septic peritonitis
(Borovikova et al., 2000); ultraviolet experimentally injured skin
(Osborne-Hereford et al., 2008); collagen-induced rheumatoid
arthritis (van Maanen et al., 2009), and more recently it was
demonstrated that nAChRα7-dependent mechanisms and sig-
naling are involved in the modulation of chronic inﬂammatory
neuropathic pain (AlSharari et al., 2013), and also neuroprotec-
tion under ischemic conditions by regulation of neuroinﬂam-
mation and oxidative stress (Parada et al., 2013).
Duchenne muscular dystrophy (DMD) is an X-linked pro-
gressive fatal myopathy caused by mutations in the gene
encoding for the cytoskeletal protein dystrophin, which is
important for organizing the membrane cytoskeleton, and
aggregating ion channels and neurotransmitter receptors
(Carlson, 1998; Hoffman et al., 1987). Lack of dystrophin
compromises the structural integrity of the cell membrane
leading to aberrant intracellular signaling cascades that reg-
ulate both inﬂammatory and immune activities and contribute
substantially to the physiopathology of muscular lesion (Evans
et al., 2009; Lagrota-Candido et al., 2002). Mdx mouse, theanimal model of human DMD, develops a benign phenotype
with a multi-staged disorder characterized by intense myone-
crosis with scattered inﬂammatory inﬁltrate at 4 weeks (4 wks)
of age followed by muscular regeneration (12 wks) and later
persistent ﬁbrosis (24 wks) (Collins and Morgan, 2003; Evans
et al., 2009; Lagrota-Candido et al., 2002). Our group observed a
modulation of nAChRα7 expression at different stages of the
mdx muscular dystrophy, and that nicotine treatment atte-
nuated muscular inﬂammation and increased muscle regen-
eration (Leite et al., 2010). This work aimed to provide
additional insight on selective activation of nAChRα7 in the
mdx muscular inﬂammation. For such purpose, we used the
α7 KO mice and pharmacological manipulation (Parada et al.,
2013) with PNU282987 and the nAChRα7 antagonist methylly-
caconitine (MLA). This approach allowed us to determine a
putative role of α7-mediated stimulation or blockade of endo-
genous cholinergic activation in the mdx muscular pathology.2. Results
2.1. Selective nAChRα7 activation reduces serum
and muscular inﬂammation in mdx mice
TNFα circulating levels were determined to verify a putative
effect of nAChRα7 activation in mdx mice inﬂammation. For
such purpose it was chosen a 7-daily treatment with
PNU282987, a selective nAChRα7 agonist used at two different
doses (0.3 and 1.0 mg/kg); the MLA antagonist (1.0 mg/kg), or
both agonist and MLA at 1.0 mg/kg. Intraperitoneal treatment of
mdx mice with low dose (0.3 mg/kg) PNU282987 reduced TNFα
circulating levels (Fig. 1A), and such effect was even more
evident (2173.3%; po0.005) following treatment with 1.0 mg/
kg dose. Conversely, treatment of mdx mice with the compe-
titive antagonist MLA at 1mg/kg abolished the effect, being
observed a slight increase on TNFα circulating levels comparing
with vehicle-treated mouse. Furthermore, in combination with
the agonist (1 mg/kg PNU282987 plus 1mg/kg MLA) completely
abolished the agonist effect, thus indicating a role for nAChRα7
in reducing the production of TNFα pro-inﬂammatory cytokine.
Next, we veriﬁed whether nAChRα7 activation could inﬂu-
ence in the production and activity of MMPs, a family of
endopeptidases which are important in normal physiological
processes and skeletal tissue remodeling (Bani et al., 2008).
Increased MMP-9 activity in the serum reﬂects a process of
active ongoing inﬂammation in several models (Khandoga
et al., 2006; Maddahi et al., 2012; Schiøtz Thorud et al., 2005).
Treatment with 1mg/kg PNU282987 caused a marked reduction
(91716%; po0.005) of MMP-9 activity in the sera and also a
signiﬁcant reduction (54718%, po0.05) in the gastrocnemius
Fig. 1 – Selective nAChRα7 activation reduces mdx inﬂammation. (A) Serum levels of TNFα determined by enzyme
immunoassay and metalloprotease (MMP) activity determined by gelatin zymography, (B) zymogram from gastrocnemius
muscle of 3 wks-old mdx mice treated for 7 days with Vehicle, PNU282987 (0.3 or 1.0 mg/kg), MLA (1.0 mg/kg), or PNU282987
plus MLA at 1.0 mg/kg. One-way ANOVA test indicates po0.05 for TNFα content; po0.005 for MMP-9 activity in the serum, and
po0.05 for MMP-9 and MMP-2 activities in the gastrocnemius muscle. Unpaired t test analysis (npo0.05; npo0.005). Four mice
were included per experimental group. Results are expressed as mean7SEM.
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induce any alteration in the MMP-9 activity, but reversed
PNU282987 agonist effect when administered concomitantly.
PNU282987 treatment did not alter active MMP-2 in the serum
(Fig. 1A) but caused a marked increase (170735% po0.05) in
mdx gastrocnemius muscle compared with sham-control (vehi-
cle) values. Such effect was reversed with combined (MLA plus
PNU282987) treatment (Fig. 1B), thus indicating a role for
nAChRα7 activation in the mdx muscular tissue remodeling.2.2. Effect of nAChRα7 activation in bupivacaine
bp-induced muscular lesion
Increased skeletal muscle remodeling during acute stages of
bp-induced inﬂammation is important for collagen degrada-
tion and facilitation of leukocyte migration with phagocytic
properties for cell debris clearance (Kherif et al., 1999;
Lagrota-Candido et al., 2010). It was chosen a self-limited
bp-induced muscular injury and applied 7-daily treatment
Fig. 2 – nAChRα7 activation inﬂuences muscular MMP activities, Zymograms from muscular lesion induced with 60 ll
bupivacaine (0.5%) injected in the gastrocnemius muscle of nAChRα7þ/þ (A) and nAChRα7/ (B) mice treated for 4 days with
Vehicle, 1.0 mg/kg PNU282987, or without any treatment (Control). One-way ANOVA test indicates po0.05 for MMP-9 and
MMP-2 activities of nAChRα7þ/þ mice. Unpaired t-test analysis (*po0.05). Four mice were included per experimental group.
Results are expressed as mean7SEM.
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observed signiﬁcant reduction (33711%; po0.05) on MMP-9
activity, and a marked increase (81713%; po0.05) on active-
MMP-2 activity in the wild-type nAChRα7þ/þ (Fig. 2A). Con-
versely, treatment with the nAChRα7 selective agonist did not
change MMP-9, pro-MMP-2 and active-MMP-2 activities in the
nAChRα7/ mice (Fig. 2B).
2.3. Selective nAChRα7 activation reduces muscle cell
death
As selective nAChRα7 activation reduced muscular inﬂam-
mation mediated by MMP-9 activity, we considered thatFig. 3 – Selective nAChRα7 activation reduces muscle cell death. (
days with Vehicle, 1.0 mg/kg PNU282987, 1.0 mg/kg MLA, or bot
nAChRα7þ/þ and nAChRα7/mice with 60 ll bp-induced muscul
with Vehicle, 1.0 mg/kg PNU282987, or PNU282987 plus MLA at
muscle cells treated with vehicle or PNU282987 at 1.0 mg/kg. Sc
were included per experimental group. Results are expressed aPNU282987 could exert a protective effect on muscular cell
membrane integrity. As an indicator for cytotoxicity damage
it was used quantiﬁcation of LDH release in the serum of
mdx, and bp-induced muscle injury of nAChRα7þ/þ and
nAChRα7/ mice. Intraperitoneal PNU282987 (1 mg/kg)
injection during 7 days reduced LDH activity in comparison
to sham-control vehicle (71716%, po0.05). Treatment of mdx
mice with 1 mg/kg MLA abolished PNU282987 effect and
further increased LDH levels in comparison to mdx sham-
control (vehicle). Furthermore, treatment of mdx mice with
PNU282987 plus MLA both at 1 mg/kg was capable to partly
reverse (po0.05) the protective effect afforded by the selective
nAChRα7 activation (Fig. 3A). Serum of nAChRα7þ/þmice withA) Graph depicts LDH serum levels of mdx mice treated for 7
h PNU282987 and MLA at 1.0 mg/kg. (B) LDH serum level of
ar injury in the gastrocnemius muscle and treated for 4 days
1.0 mg/kg. (C) Images of Evans blue incorporation by mdx
ale bar 100 lm. Unpaired t-test analysis (*po0.05). Five mice
s mean7SEM.
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selective nAChRα7 activation showed marked reduction
(79730%, po0.05) on LDH activity compared to control-
sham mice receiving vehicle. Combined drug treatment
(PNU282987 plus MLA) abolished (po0.05) the effect. Conver-
sely, drug treatment of nAChRα7/KO mice with bp-induced
muscular lesion did not change the pattern of LDH activity in
the serum (Fig. 3B). To establish a relation of nAChRα7
selective activation with reduced LDH serum levels and
myoblast membrane integrity mice received Evans blue dye
24 h before sacriﬁce. Evans blue dye was almost excludedFig. 4 – nAChRα7 activation reduces mdx muscular lesion and i
IB4 biotin antibody and streptavidin Cy3 conjugate (white arrow
blood vessels in the gastrocnemius muscle (white dots) of mdx
1.0 mg/kg MLA, or PNU282987 plus MLA at 1.0 mg/kg, in contra
show areas with inﬂammatory inﬁltrate and regeneration of md
1.0 mg/kg PNU282987. Scale bar 100 lm. (C) Morphometric analy
collagen deposition in mdx gastrocnemius muscle. (D) Morphom
gastrocnemius muscle of nAChRα7þ/þ and nAChRα7/ after tre
Unpaired t test analysis (npo0.05; npo0.005). Seven mdx, and fo
experimental group. Results are expressed as mean7SEM.from mdx skeletal muscle ﬁbers in mdx mice treated with
1.0 mg/kg PNU282987 which showed few red-ﬂuorescent
muscle ﬁbers, an indication that treatment exerted a protec-
tive effect reducing myoblast necrosis (Fig. 3C).
2.4. Selective nAChRα7 activation reduces mdx
muscular lesion
Extravasation of inﬂammatory leukocytes from activated
vascular endothelial cells into the site of injury is involved
in the physiopathology of mdx muscular lesion by eithermproves regeneration (A) Depicts blood vessels labeled with
s); and area of perivascular inﬂammatory inﬁltrate nearby
mice treated for 7 days with Vehicle; 1.0 mg/kg PNU282987;
st to nAChRα7þ/þ control mice. (B) Histological micrographs
x gastrocnemius muscle after treatment with Vehicle or
sis of foci with inﬂammatory inﬁltrate, regeneration and
etric analysis of foci with inﬂammatory inﬁltrate in the
atment with Vehicle or 1.0 mg/kg PNU282987 for 4 days.
ur nAChRα7þ/þ and nAChRα7/ mice were included per
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B4 (IB4) immunolabeling was used as histochemical marker
to assess the inﬂuence of nAChRα7 selective activation on
vascular endothelia of mdx mice.
A slight IB4 immunolabeling was observed in the control
wild-type nAChRα7þ/þ muscular tissues. In contrast, after
7-days treatment with vehicle control-sham mdx mice
showed an intense perivascular inﬂammatory inﬁltrate
(Fig. 4A). Treatment of mdx mice with 1.0 mg/kg PNU282987
reduced the area of perivascular inﬂammatory inﬁltrate and
also the presence of IB4 positive active endothelia. Treatment
with the competitive antagonist MLA reversed the anti-
inﬂammatory effect of PNU282987 (Fig. 4A). Morphometric
analysis conﬁrmed that treatment of mdx mice with the
selective nAChRα7 agonist PNU282987 reduced the area of
inﬂammatory inﬁltrate (49713%, po0.005) and increased
(34712%, po0.05) the percentage of regenerating myoﬁbers
characterized by strong basophilic and centrally located
nuclei. Treatments did not cause signiﬁcant changes (Fig. 4B
and C) in sirius red staining, used as a parameter of collagen
deposition in the muscular microenvironment. Histological
analysis of gastrocnemius muscle of nAChRα7þ/þ mice with
bp-induced muscular lesion showed a signiﬁcant reduction of
inﬂammatory inﬁltrate area (38%711%, po0.05) after selec-
tive nAChRα7 activation with PNU282987. In contrast, the
experimentally injured muscle nAChRα7/ mice did not
show any alteration after treatment (Fig. 4D).3. Discussion
Excessive inﬂammatory signaling is the underlying pathogenic
mechanism leading to tissue damage in chronic inﬂammatory
diseases, although activation of distinct anti-inﬂammatory
pathways triggers the process of wound healing and tissue
repair (Murray and Smale, 2012). Indeed, activation of endo-
genous pathways responsible for regulating inﬂammationmay
restraint exacerbated immune response and activate diverse
mechanisms that promote muscle regeneration in the mdx
mouse, a model of inﬂammatory myopathy (Leite et al., 2010).
Data from various experimental models of inﬂammation
point towards the nAChRα7 being crucial for cholinergic
modulation of inﬂammation (AlSharari et al., 2013; Parada
et al., 2013). Although in vitro response to high nAChRα7
agonist concentrations rapidly desensitize the receptor for a
long period (AlSharari et al., 2013), in vivo treatment with
nicotine was capable to signiﬁcantly reduce mdx inﬂamma-
tory lesion and increase muscle regeneration (Leite et al.,
2010). Indeed, the α7 subunit-containing nicotinic acetylcho-
line receptor (nAChRα7) is an essential component in the
cholinergic anti-inﬂammatory pathway regulating the levels
of TNF, high mobility group box 1 (HMGB1), and other
cytokines during inﬂammation (Parrish et al., 2008; Pavlov
and Tracey, 2012).
To provide additional insight on the role of the α7 nAChR
in mdx chronic muscular inﬂammation, we used the α7 KO
mice and in vivo pharmacological manipulation with
PNU282987, a highly selective nAChRα7 agonist that cause
minor side effects than nicotine, and the MLA antagonist
(Wang et al., 2004). The spleen is a primary target for signalsin the efferent pathway of the inﬂammatory reﬂex, because
almost all TNF released systemically in the early phase of
rodent endotoxemia originates in the spleen (Olofsson et al.,
2012). We observed that repeated administration of PNU282987
markedly reduced circulating levels of proinﬂammatory TNFα
cytokine and MMP-9 activity in the serum, and also in mdx
gastrocnemius muscle.
Matrix metalloproteases MMP-2, MMP-9 and also MMP-10
are directly involved in muscle plasticity being essential for
skeletal muscle maintenance and regeneration in muscular
dystrophies and sarcolemmal damage associated with
mechanical injury (Bani et al., 2008; Bobadilla et al., 2014;
Li et al., 2009; Rullman et al., 2007). Since MMP-9 is up-
regulated at the height (3 wks-old) of the mdx myonecrosis
(Bani et al., 2008; Li et al., 2009), a role for nAChRα7 in
reducing mdx muscle inﬂammation was further conﬁrmed
with experiments showing MLA-induced reversion of the
agonist stimulatory effect. Moreover, the nAChRα7 agonist
was also capable to activate mdx muscle regeneration, as
in vivo treatment with PNU282987 agonist also increased
MMP-2 activity and the area with basophilic myoblasts
characteristic of muscle regeneration. In addition, treatment
did not reduce tissue inﬂammation in nAChRα7/ mice with
bp-induced muscular lesion. This is an indication that selec-
tive nAChRα7 activation reduces the inﬂammatory signaling
mediated by metalloprotease MMP-9 important for TNFα
cleavage into 17-kDa mature form and the inﬂammatory
pleiotropic actions of NFkB transcription factor signaling
pathway. Interestingly NFkB activity in mdx muscle is loca-
lized in both dystrophic muscle and immune cells, and
persistent NFkB signaling exacerbates production of pro-
inﬂammatory mediators that promotes muscle necrosis and
limits skeletal muscle ﬁber regeneration through inhibitory
effect on muscle progenitor cells (Acharyya et al., 2007).
The abnormal clustering of acetylcholine receptors (AChR) on
mdx skeletal muscle ﬁbers compromises the formation of
neuromuscular junction and functional integrity of skeletal
muscles leading to massive inﬁltration of inﬂammatory cells,
necrosis, and severe muscle degeneration characterized by
increased leakage of cytosolic LDH and creatine kinase enzymes.
Treatment with the nAChRα7 agonist PNU282987 reduced LDH
release in the serum and myoﬁber necrosis of mdx and
nAChRα7þ/þ with bp-muscular lesion. Therefore, selective acti-
vation of nAChRα7 in both experimental models was capable to
prevent development of muscular degeneration. Moreover, selec-
tive nAChRα7 activation also increased MMP-2 activity in skeletal
muscles from both mdx and nAChRα7þ/þ with bp-muscular
lesion. This is an indication that nAChRα7 activation directly
inﬂuences tissue remodeling by increasing muscular regenera-
tion without inducing ﬁbrosis and/or deposition of non-
functional collagen. The hypothesis that nAChRα7 has a relevant
involvement as a regulator of muscle inﬂammation and tissue
remodeling is consistent because experimentally injured muscle
nAChRα7/ mice did not show reduction on MMP-9 activity or
modulation of active-MMP-2 after PNU282987 treatment. These
data strongly suggest that metalloprotease balance is crucial for
a switch between pro-inﬂammatory to tissue remodeling phe-
notype, and that nAChRα7 selective activation positively inﬂu-
ence this phenomenon. Altogether the results indicate that
nAChRα7 activation may be considered as a potential target for
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mechanisms of muscular tissue remodeling.4. Experimental procedure
4.1. Animal care
The animal use procedures were approved by the institu-
tional animal care and used according to the guidance of
Ethics Committee for Handling Research Animals of the
Committee of Animal Experimentation from the Fluminense
Federal University (CEUA-UFF, Brazil), and of the Medical
School of Universidad Autónoma de Madrid (UAM-Spain).
Male mdx dystrophic and age-matched wild type non-
dystrophic mice (both C57BL/10 background) were main-
tained at the Cellular Pathology animal house facilities of
the Institute of Biology, UFF, and male nAChRα7 knockout
(/ ) and age-matched nAChRα7 wild type (þ/þ) mice (both
C57BL/6 background) at Universidad Autónoma de Madrid.
Mice were kept at constant temperature (21 1C) with a light
cycle of 12 h. Mdx and control mice were sacriﬁced in the
period of inﬂammatory prevalence at 4 weeks, and
nAChRα7/ and respective control mice at 6 weeks age.
4.2. Inﬂammatory model – induction of muscular lesion
nAChRα7þ/þ and nAChRα7/ (KO) mice at 6 wks of age were
anesthetized by intraperitoneal injection with ketamine
(100 mg/Kg) and xylazine (10 mg/Kg). Muscular lesion was
performed as previously described (Mussini et al., 1987) in the
central region of gastrocnemius muscles. Ipsilateral muscle
was injected with 60 mL 0.5% bupivacaine hydrochloride (bp)
(Sigma-Aldrich, Spain), and the contralateral muscle (control-
sham) with vehicle.
4.3. In vivo pharmacological treatment
Mdx mice at 3 wks (21 days postnatal – PN) received daily
intraperitoneal injections of 0.3 or 1 mg/kg PNU282987 (N-
(3R)-1-Azabicyclo[2.2.2]oct-3-yl-4-chlorobenzamide) (Tocris
Bioscience, Bristol, UK) or vehicle saline solution during 7
days. nAChRα7/ and nAChRα7þ/þ mice with bp-induced
muscular lesion were equally treated during 4 days. Groups
were also treated with the nAChRα7 antagonist methyllyca-
conitine citrate ([1α,4(S),6β,14α,16β]-20-Ethyl-1,6,14,16-tetra-
methoxy-4-[[[2-(3-methyl-2,5-dioxo-1-pyrrolidinyl)benzoyl]
oxy]methyl]aconitane-7,8-diol citrate) (MLA 1029, Tocris
Bioscience, Bristol, UK) at 1 mg/kg or PNU282987 together
with MLA (both at 1 mg/kg). Mice were sacriﬁced at the end of
treatment for blood and tissue collection. At least 4 animals
were included in each group, and experiments were repeated
three times.
4.4. Quantiﬁcation of TNFα by ELISA assay
Mice sera used for determination of TNFα levels were quantiﬁed
in triplicate by commercial enzyme-linked immunosorbent
assay (ELISA) according to the manufacturer's instructions
(PeproTech Inc., NJ, USA). Absorbance was assessed in amicroplate spectrophotometer (Thermo Scientiﬁc™ Multiskan
FC, USA) at wavelength 450 nm and also 650 nm correction ﬁlter
after addition of 1% SDS stopping solution.
4.5. Gelatin zymography for detection of metalloprotease
activity
Serum was immediately frozen in aliquots and preserved at
80 1C until use. Gastrocnemius muscles were removed,
homogenized (TBS 1/10 w/v, 100 mM Tris–HCl pH 7.6,
200 mM NaCl, 100 mM CaCl2 and 1% Triton X-100) then
clariﬁed by centrifugation at 15,000g for 10 min at 10 1C, and
protein quantiﬁcation determined by the Lowry method.
Equal amounts of total protein were loaded (60 μg/lane for
muscle; 20 μg/lane for serum) and metalloprotease activity
determined by zymography as previously described (Kherif
et al., 1999; Leite et al., 2010). Gelatinase activity was visua-
lized as unstained bands on a blue background representing
areas of proteolysis. Metalloproteases are secreted in a latent
form and require cleavage of a NH2 terminus peptide for
activation. Exposure of proenzymes to SDS during gel separation
leads to activation without proteolytic cleavage (Talhouk et al.,
1992) with appearance of bands corresponding to 100-kDa (MMP-
9), 66-kDa (pre-pro-MMP-2) and 60-kDa (pro-MMP-2), and less
frequently 55-kDa (active-MMP-2) (Kherif et al., 1999). Semi-
quantitative analysis was performed by using image analysis
software (Scion Image, NIH, Bethesda, Md., USA).
4.6. Histological staining and morphometric analysis
Gastrocnemius muscles were removed and ﬁxed in formalin-
buffered Millonig ﬁxative (pH 7.2) for 24 h. Sections (10 μm
thick) of tissue embedded in paraplast (Sigma, St. Louis, Mo.,
USA) were stained with hematoxylin and eosin and sirius red
to analyze histological alterations and collagen deposition
respectively. Degenerating and necrotic ﬁbers were identiﬁed
by homogeneous pale eosinophilic sarcoplasm, whereas
regenerating ﬁbers were characterized by strong basophilic
and centrally-located nuclei. High-deﬁnition whole-area
images of all cross sections from a single mouse at each time
point were acquired from individual photomicrographs with
a microdigital camera mounted on a Zeiss Axioplan micro-
scope (Zeiss, Oberkochen, Germany) by using a 20 objec-
tive. Images were blended by using Adobe Photoshop CS3
Extended software. Total surface area, areas occupied by
inﬂammatory inﬁltrate, regenerating myoﬁbers and collagen
deposition were determined with Image-Pro 4.5 (Media
Cybernetics). For analysis of perivascular inﬂammatory inﬁl-
trate nearby blood vessel, sections were also stained for
isolectin B4 (Isolectin GS-IB4 1:100; Vector, Burlingame, CA,
USA), and its extension in each image demarcated by white
dots. Results are expressed as percentage of total area in the
cross-section.
4.7. Immunoﬂuorescence
10 mm slices were washed with PBS and incubated for 1 h with
blocking buffer (0.05% Triton X-100 in PBS, containing 5%
normal goat serum). For labeling endothelial cells, samples
were incubated for 2 h at 4 1C with biotinylated Griffonia
b r a i n r e s e a r c h 1 5 7 3 ( 2 0 1 4 ) 2 7 – 3 6 35simplicifolia I isolectin B4 (1:100; Vector, Burlingame, CA, USA),
followed by 1 h incubation with streptavidin Cy3-conjugate
(1:1000; Jackson Immuno Research; West Grove, PA, USA) at
room temperature and counterstained with Dapi. Images
were obtained with a Nikon Eclipse TE2000-U microscope
(Olympus, Tokyo, Japan) with identical time exposure and
image settings and merged on Adobe Photoshop CS5.4.8. Assessment of muscle damage
Lactate dehydrogenase (LDH) release was used to verify cell
death by necrosis. LDH activity was measured with CytoTox
96s colorimetric, non-radioactive, cytotoxicity assay (Pro-
mega Corp. Madison, WI, USA). Brieﬂy, serum was diluted
and incubated in a 1:2 dilution with substrate at room
temperature for 30 minutes. Stop solution was added to each
well and absorbance recorded with a 490 nm ﬁlter in an ELISA
reader. Evans blue dye (10 mg/ml in PBS pH 7.4) injected
intraperitoneally 24 h before sacriﬁce allows observation of
in vivo myoﬁber damage (Crawford et al., 2000). At the end of
drug treatment, mice were sacriﬁced and muscles were
removed, frozen in OCT (Tissue-Tek, Elkhard, IN,USA) embed-
ding medium, and Evans blue uptake by individual ﬁbers in
10 mm-thick frozen sections were ﬁxed in cold acetone for
image analysis in a Nikon Eclipse TE2000-U microscope
(Olympus, Tokyo, Japan) with identical time exposure and
image settings.4.9. Quantitative and statistical analysis
Gelatin zymograms, histological staining and morphometry
were analyzed using Scion Image for Windows software
(Scion Corporation, National Institutes of Health; Bethesda,
MD). GraphPad Prism 5 (GraphPad software Inc.) was used to
calculate mean and standard errors. One-way ANOVA and
unpaired t test were applied to obtain statistical signiﬁcance
of means. Differences were considered to be statistically
signiﬁcant at the 0.05 level of conﬁdence.Funding
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